Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development
I'm PortAI, I can summarize articles.
Traws Pharma Inc. has extended its contract with ChemDiv for CMC services to support the clinical development of ratutrelvir, an oral antiviral for COVID-19 in Phase 2 trials. The agreement includes CMC process research, medicinal chemistry support, and clinical pharmacology consulting. Additionally, Expert Systems has also extended its contract with Traws Pharma for predictive safety pharmacology services using AI to aid further clinical development of ratutrelvir.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments